Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hepalink Pharma Posts Lower Q3 Results

publication date: Oct 19, 2011
Shenzhen Hepalink Pharma, a maker of heparin products, reported its Q3 profits fell 58% to 148 million RMB ($23 million). Hepalink blamed the shortfall on a drop in the price of heparin API. In the past, Hepalink was the only China heparin API company whose products were certified by the FDA. It lost that advantage when a competitor was also granted FDA certification. More details....

Stock Symbol: (SHE: 002399)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital